Literature DB >> 27169165

THROMBOTIC MICROANGIOPATHY ASSOCIATED WITH OPANA ER INTRAVENOUS ABUSE A Case Report.

Fadi I Jabr, Ling Yu.   

Abstract

Thrombotic microangiopathy is characterized by endothelial changes and microvascular stenosis. Several entities such as pregnancy, infection, connective tissue diseases, and drugs are associated with secondary thrombotic microangiopathy. Recently, new reformulation of Opana ER had been associated with thrombotic microangiopathy when injected intravenously. Here, we report the case of a 37-year-old man who developed renal failure and hemolytic anemia secondary to Opana ER intravenous abuse. Renal biopsy pathology was consistent with thrombotic microangiopathy likely caused by Opana ER intravenous abuse.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27169165     DOI: 10.12816/0023831

Source DB:  PubMed          Journal:  J Med Liban        ISSN: 0023-9852


  4 in total

1.  A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER.

Authors:  Ryan Hunt; Ayla Yalamanoglu; James Tumlin; Tal Schiller; Jin Hyen Baek; Andrew Wu; Agnes B Fogo; Haichun Yang; Edward Wong; Peter Miller; Paul W Buehler; Chava Kimchi-Sarfaty
Journal:  Blood       Date:  2016-11-18       Impact factor: 22.113

Review 2.  Systematic review of nephrotoxicity of drugs of abuse, 2005-2016.

Authors:  Kanaan Mansoor; Murad Kheetan; Saba Shahnawaz; Anna P Shapiro; Eva Patton-Tackett; Larry Dial; Gary Rankin; Prasanna Santhanam; Antonios H Tzamaloukas; Tibor Nadasdy; Joseph I Shapiro; Zeid J Khitan
Journal:  BMC Nephrol       Date:  2017-12-29       Impact factor: 2.388

3.  Opana-induced thrombotic microangiopathy masquerading as thrombotic thrombocytopenic purpura.

Authors:  Byung H Ban; Ashish Verma; Maria Tudor; Jigme Sethi
Journal:  Oxf Med Case Reports       Date:  2017-06-01

Review 4.  Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.

Authors:  Richard L Rauck
Journal:  Pain Pract       Date:  2019-02-28       Impact factor: 3.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.